Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | PTAFR | P25105 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | MELK | Q14680 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79595 | 0.75 | MAPK14 (0.35) | MAPK14DAOPTAFRDPP4 | |
| SCHEMBL16056864 | 0.71 | DAO (0.42) | MAPK14DAO | |
| SCHEMBL14072752 | 0.70 | — | — | |
| SCHEMBL8013270 | 0.67 | DPP4 (0.51) | MAPK14TSHRDPP4 | |
| SCHEMBL6847889 | 0.67 | MAPK14 (0.51) | MAPK14MELKDPP4 | |
| SCHEMBL6854322 | 0.67 | HDAC1 (0.41) | MAPK14MELKDPP4 | |
| SCHEMBL7575258 | 0.67 | G6PC1 (0.35) | PTGDR2ADORA3 | |
| SCHEMBL13722953 | 0.66 | DPP4 (0.39) | DPP4 | |
| SCHEMBL6854759 | 0.66 | MAPK14 (0.38) | MAPK14MELKDPP4 | |
| SCHEMBL6869609 | 0.65 | KDM4E (0.55) | PTAFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| EP-0891363-B1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 2003-08-27 | — | — | EP | disclosed |
| EP-0900218-B1 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1051176-A4 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARM PROD INC (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-0900218-A4 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-0900219-A4 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-0900217-A4 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-0900204-A4 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-0900219-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| EP-0900217-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| EP-0900204-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| EP-0900218-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| EP-0891363-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997040016-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997040044-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997040042-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997040043-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997036906-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | PTGDR2 936/4885MAPK14 3982/4885TSHR 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.